Every material Form 8-K Altimmune, Inc. has filed with the SEC since September 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Altimmune drew $10.0 million as Tranche Three of its $125.0 million Loan and Security Agreement with Hercules Capital after meeting certain clinical and financial milestones. The draw extends the amortization date and interest-only period to June 1, 2028, and adds a minimum cash requirement tied to the loan balance, which shareholders may want to weigh against the company's cash position.
Tranche Three draw of $10.0 million made October 27, 2026, under the loan agreement dated May 13, 2025, as amended November 5, 2025
Amortization date and interest-only period extended to June 1, 2028
Company must keep Qualified Cash at or above 60% of outstanding Term Loan Advances principal
A 1.0% Tranche Facility Charge was netted from funding; end-of-term charge is 6.25% of amounts funded
Altimmune said its board appointed Peter Greenleaf and Alex Howarth as directors effective November 2, 2026, increasing the board from nine to eleven seats. Three current directors, John Gill, Mitchel Sayare and Klaus Schafer, will retire at the 2027 annual meeting rather than stand for re-election, and the company said their departures are not due to any disagreement with the company.
Peter Greenleaf (54), former CEO of Aurinia Pharmaceuticals, and Alex Howarth (58), former CFO of Madrigal Pharmaceuticals, join the board effective November 2, 2026.
Board size increases from nine to eleven directors.
Gill, Sayare and Schafer continue as directors until the 2027 Annual Meeting, then retire.
Each new director receives an initial stock option award for 160,000 shares and a $40,000 annual cash retainer.
Altimmune appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. CFO Gregory Weaver remains in his role, so the change is limited to the company's accounting leadership.
Appointment made by the Board on September 24, 2026, effective September 29, 2026
Menziuso has 28 years of finance and accounting experience, including 12 years in public accounting
Previously Vice President, Corporate Controller at Centessa Pharmaceuticals from 2021 until its 2026 acquisition by Eli Lilly
Gregory Weaver will remain Chief Financial Officer
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Altimmune, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →